8 January 2026 - Australians living with a range of debilitating conditions including juvenile arthritis, rare liver disease and multiple sclerosis will pay less for newly listed PBS listed medicines, thanks to the Albanese Government.

Adalimumab (Humira) will be expanded to treat juvenile idiopathic arthritis, alongside other paediatric immune-mediated inflammatory diseases for which it is already listed, including Crohn’s disease, ulcerative colitis and chronic plaque psoriasis.

Read Minister for Health article